
Temasek's Ion Investments to divest stake in South Korean pharma for $1.35b block deal

SINGAPORE (Mar 7): Ion Investments, which is controlled by Temasek Holdings of Singapore, is selling part of its stake in South Korean pharmaceutical company Celltrion and distributor Celltrion Healthcare, IFR reported on Tuesday, citing a term sheet.
In a block deal worth up to 1.1 trillion won ($1.35 billion), Ion plans to sell up to 2.24 million shares in Celltrion for 336,700 to 347,800 won each and up to 2.29 million shares in Celltrion Healthcare for 108,654 to 112,236 won each, IFR said.
The pricing represents a discount of 6-9% to their pre-deal close, said IFR, a Thomson Reuters publication.
Tags: Temasek - Ion Investments - Celltrion - Celltrion Healthcare - IFR - Reuters
To continue reading,
Sign in to access this Premium article.
Subscription entitlements:

Less than $9 per month

3 Simultaneous logins across all devices

Unlimited access to latest and premium articles

Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
Related Stories
- Former DBS CEO Piyush Gupta to be chairman of Temasek India
- Southeast Asia’s AI buildout accelerates as digital economy hits US$300 bil: report
- Schneider is said in talks to buy Temasek’s stake in Indian JV